Mural Oncology plc (MURA)
- Previous Close
3.5300 - Open
3.5400 - Bid 3.5500 x 400
- Ask 3.5900 x 400
- Day's Range
3.4800 - 3.6400 - 52 Week Range
3.2300 - 6.2500 - Volume
95,645 - Avg. Volume
246,542 - Market Cap (intraday)
60.583M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
13.00
Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
www.muraloncology.comRecent News: MURA
Performance Overview: MURA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MURA
Valuation Measures
Market Cap
60.58M
Enterprise Value
-195.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
1.01
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-72.52%
Return on Equity (ttm)
-171.33%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-207.45M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
270.85M
Total Debt/Equity (mrq)
5.69%
Levered Free Cash Flow (ttm)
-112.89M
Research Analysis: MURA
Analyst Price Targets
Fair Value
No Fair Value available for this ticker